

Supplemental Figure

Selected tandem mass spectra for labeled peptides. (A) P49773 Protein kinase C inhibiting protein 1 (**144Y**): M]VVNEGSDGGQSVY#HVHLHVLGGR; (B) P06733 α -Enolase (**144C**): S]GETEDTFIADLVVGLC#TGQIK*; (C) P52948 Nup 98-Nuclear pore complex protein (**42K**): LYQTPLELK#LK*; (D) P63313 Thymosin beta-10 (**43K**): A]DK#PDMGEIASFDK*AK*; (E) P05783 Cytokeratin-18 (**16M**): Y]ALQM#EQLNGILLHLESELAQTR.


Note 1: In the peptide amino acid sequence: “]” and “*” indicate the iTRAQ tag at the Nt and Lys residues, respectively; “#” indicates the additional amino acid modification.

Note 2: Fragment **b/y** ions that carry the modification and immediately adjacent to the modification are provided in boxes; the modification site is provided in *bold*.

Note 3: In tandem mass spectra: “o” represents ions that lost one molecule of H₂O; “*” represents ions that lost one molecule of NH₃; “T” represents internal fragments.

Note 4: In tandem mass spectrum **A**, the site of modification (**y₁₁**) could not be assigned. However, the presence of Nt sequence ions (**b₁**, **b₂**, **b₃**, **b₄**, **b₅**), of **y₅**, **y₆**, **y₇**, **y₈**, **y₉**, and **y₁₀** ion series before the modification, and of good Sequest scores, confirmed the iTRAQ labeling of the Tyr residue. In tandem mass spectra **2B/C/D/E**, the precise site of modification was assigned. The **b/y** ions adjacent and at the modification site are provided in boxes, the modification site being provided in *bold*.

#5951-5951 RT:76.75-76.75 NL:2.81E1



#15713-15713 RT:189.14-189.14 NL:1.29E2






Figure B



#6097-6097 RT:7620-7620 NL: 7.14E2



#16756-16756 RT201.80-201.80 NL: 2.62E2




Figure E